Bioanalysis Zone

Development and validation of an ELISA to study panitumumab pharmacokinetics

0

Aim: Panitumumab is a monoclonal antibody directed against EGFR that is approved for the treatment of metastatic colorectal cancer. To investigate its pharmacokinetics and concentration–response relationship, a validated assay is required.

Results: An ELISA assay was developed and validated according to international recommendations. Six calibrators (ranging from 0.1 to 20 mg/l) plus one anchor point (50 mg/l) and three

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Click here to read the full article in Bioanalysis.

Share:

Leave A Comment